ERAS
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Erasca, Inc. (ERAS) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Profitability (C). The rating has held at C+ for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | C (2.5) | C (2.4) | B (3.2) | C+ (2.6) | C+ (2.6) |
| 2026-11-04 | C+ (2.5) | C (2.5) | C (2.4) | B (3.2) | C+ (2.7) | C+ (2.6) |
| 2026-10-28 | C+ (2.5) | C (2.4) | C (2.4) | B- (3.1) | C+ (2.7) | C+ (2.6) |
| 2026-10-21 | C+ (2.5) | C (2.4) | C (2.4) | C- (2.1) | C+ (2.6) | C (2.4) |
| 2026-10-14 | C+ (2.5) | C (2.4) | C (2.4) | C (2.4) | C+ (2.6) | C (2.5) |